` RCEL (AVITA Medical Inc) vs S&P 500 Comparison - Alpha Spread

RCEL
vs
S&P 500

Over the past 12 months, RCEL has underperformed S&P 500, delivering a return of -36% compared to the S&P 500's 10% growth.

Stocks Performance
RCEL vs S&P 500

Loading
RCEL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RCEL vs S&P 500

Performance Gap Between RCEL and GSPC
HIDDEN
Show

Performance By Year
RCEL vs S&P 500

Loading
RCEL
S&P 500
Add Stock

Competitors Performance
AVITA Medical Inc vs Peers

S&P 500
RCEL
ABBV
AMGN
GILD
VRTX
Add Stock

AVITA Medical Inc
Glance View

Market Cap
136.1m USD
Industry
Biotechnology

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

RCEL Intrinsic Value
HIDDEN
Show
Back to Top